RE: 8 months - conclusion21 Apr 2022 07:16
DE + Trial progression (8 months and counting with no patient showing disease progression)) are sufficient for me to have strong belief that we have a working Precision platform but, for those that need more, simple refer to the post from Energy below....
Why present to AACR if it’s not working.
If it’s not working.
Why take biopsies if not needed in phase 1a
If it’s not working.
Why keep adding to the board of directors with world class oncology experts with 20 million left in the bank.
If it’s not working.
Why start recruiting in Glasgow with Sheffield and Newcastle also getting ready to recruit patients.
If it’s not working.
Why extend to two trial sites in USA.
If it’s not working.
Why DE and inform shareholders 2 x more DE by the end of 1b
If it’s not working.
Why is Point Bio with a licence to use precision very close to its ATH SP.
If it’s not working.
Why select precision’s next drug 3996.
If it’s not working.
Why move therapeutics laboratories just 60 miles from Cambridge to London
If it’s not working.
Why 8 months into trial with a safety committee meeting every two weeks and Avacta board members keep repeating Remarkably consistent data would the trial keep going.
If it’s not working.
Why spend 18 months developing a covid test and just as you receive Home Use Authorisation and have a second manufacturer complete TT with a world wide distribution partner in place ,then pull the test because it is not as sensitive on the latest variant. Which could damage the reputation of Avacta’s lead cancer trial AVA6000.
If it’s not working.